Prevnar 20™
Pneumococcal 20-valent Conjugate Vaccine

# Broad serotype coverage against pneumococcal disease[1-3]

Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) helps protect against the 20 *Streptococcus pneumoniae* serotypes in the vaccine[1]


- ✓ A conjugate vaccine built on the efficacy of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria $CRM_{197}$ Protein])[1,2,4]
- ✓ Delivers the most serotypes in a pneumococcal conjugate vaccine by adding 7 serotypes to Prevnar 13[1-3]
- ✓ Three phase 3 studies involving more than 6000 adult participants[1]
  - Age ≥18, pneumococcal vaccine-naïve (safety and pivotal immunogenicity study)
  - Age ≥65, prior pneumococcal vaccination (safety and immune response study)
  - Age 18-49, pneumococcal vaccine-naïve (safety and lot consistency study)

## Contains serotypes that help protect against more cases of IPD and community-acquired pneumonia


### Proportion of cases caused by serotypes in pneumococcal conjugate vaccines

**There are currently no studies comparing the efficacy of Prevnar 20™ to a 15-valent pneumococcal conjugate vaccine.**

**IPD, 2017-2018[5*]**




**CAP, 2013-2016[6,7†‡]**




*Percentages based on surveillance data collected by the Centers for Disease Control and Prevention in 2017-2018.

†Percentages based on data gathered from hospitalized adults ≥18 years with radiologically confirmed CAP in 10 US cities between October 2013 and September 2016. Urine was tested using BinaxNOW® and a serotype-specific urine antigen detection (UAD) assay that detects serotypes contained in PCV13 plus 6C (highly-related to 6A), 7 PCV20-unique serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) plus 15C (highly related to 15B), and non-PCV serotypes 2, 9N, 17F, and 20.[7]

‡Prevnar 13 and Prevnar 20 are the only conjugate vaccines approved for the prevention of pneumococcal pneumonia.[1-3]

§15 serotypes include all Prevnar 13 serotypes and the additional serotypes 22F and 33F.[3]

CAP = community-acquired pneumonia; IPD = invasive pneumococcal disease.

## INDICATIONS

- Prevnar 20 is indicated for active immunization for the prevention of pneumonia and invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
- The indication of Prevnar 20 for the prevention of pneumonia caused by *S. pneumoniae* serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
- Prevnar 13 is indicated for active immunization for the prevention of pneumonia and invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older

**Prevnar 13 Limitations of Use:** Prevnar 13 will only help protect against *S. pneumoniae* serotypes in the vaccine

**IMPORTANT SAFETY INFORMATION** (continued on page 2)

- Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20, Prevnar 13, or to diphtheria toxoid is a contraindication
- Safety and immunogenicity data on Prevnar 20 are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20
- Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13

**Please see additional Important Safety Information on page 2. Please click for Prevnar 20 and Prevnar 13 full Prescribing Information. Prevnar 20 full Prescribing Information is also available at https://www.prevnar20hcp.com/. Prevnar 13 full Prescribing Information is also available at https://www1.pfizerpro.com/product/prevnar-13/adult**

Prevnar 20™
Pneumococcal 20-valent Conjugate Vaccine

## Pneumococcal disease may result in costly hospital stays

### Mean adult inpatient length of stay, 2017[8*]

- Invasive pneumococcal disease: **7.2 days**
- Pneumococcal pneumonia: **5.1 days**


### Mean adult inpatient costs, 2017[8*]

- Invasive pneumococcal disease: **$17,966**
- Pneumococcal pneumonia: **$11,549**

*AHRQ HCUPnet data for discharges with ICD-10 codes for pneumococcal pneumonia (J13) and IPD (A40.3, sepsis due to *S. pneumoniae*; B95.3, *S. pneumoniae* as cause of other diseases; G00.1, pneumococcal meningitis; M00.1, pneumococcal arthritis and polyarthritis; M00.2, other streptococcal arthritis; R78.81, bacteremia, combined).[8]

AHRQ = Agency for Healthcare Research and Quality; HCUP = Healthcare Cost and Utilization Project.

## 2019 pneumococcal vaccination rates† fall short of national goals[9,10]




†Receipt of any pneumococcal vaccine, Behavioral Risk Factor Surveillance System, 2019.
‡Department of Health and Human Services US National Vaccine Plan.

**IMPORTANT SAFETY INFORMATION** (continued from page 1)

- For Prevnar 20, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in adults 18 through 59 years of age
- For Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria $CRM_{197}$ Protein]), in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash
- Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20, Prevnar 13, or to diphtheria toxoid is a contraindication

**Please see Indications and additional Important Safety Information on page 1. Please click for Prevnar 20 and Prevnar 13 full Prescribing Information. Prevnar 20 full Prescribing Information is also available at https://www.prevnar20hcp.com/. Prevnar 13 full Prescribing Information is also available at https://www1.pfizerpro.com/product/prevnar-13/adult**

**1.** Prevnar 20 Prescribing Information, Wyeth Pharmaceuticals LLC, 2021. **2.** Prevnar 13 Prescribing Information, Wyeth Pharmaceuticals LLC, 2019. **3.** Vaxneuvance™ (pneumococcal 15-valent conjugate vaccine) Prescribing Information. Whitehouse Station, NJ: Merck. July 2021. Accessed September 2, 2021. https://www.merck.com/product/usa/pi_circulars/v/vaxneuvance/vaxneuvance_pi.pdf **4.** Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *N Engl J Med*. 2015;372(12):1114-1125. **5.** Poehling K, Kobayashi M. Introduction of the pneumococcal work group. National Center for Immunization and Respiratory Diseases. October 28, 2020. Accessed September 2, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-10/pneumo-01-Poehling-Kobayashi-508.pdf **6.** Grant LR, Ramirez J, Self WH, et al. Streptococcus pneumoniae serotype distribution and coverage of pneumococcal conjugate vaccines in adults hospitalized with community-acquired pneumonia in the US. Presented at the virtual 12th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-12). May 4, 2020; Toronto, Canada. **7.** Isturiz R, Grant L, Gray S, et al. Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-Acquired Pneumonia in Hospitalized US Adults. *Clin Infect Dis*. 2021.[Epub ahead of print]. **8.** Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project database. Data queries accessed December 4, 2020. **9.** Centers for Disease Control and Prevention. AdultVaxView vaccination coverage among adults. Updated May 14, 2021. Accessed September 2, 2021. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/data-reports/generalpopulation/index.html **10.** US Department of Health and Human Services. Vaccines National Strategic Plan for the United States 2021–2025. January 19, 2021. Accessed September 2, 2021. https://www.hhs.gov/sites/default/files/HHS-Vaccines-Report.pdf

Manufactured by Wyeth Pharmaceuticals LLC.
PP-PNR-USA-0168-02 © 2021 Pfizer Inc. All rights reserved.

Marketed by Pfizer Inc.
November 2021